Sign in →

Test Code AK5IS Adenylate Kinase 5 (AK5) IgG, Tissue Immunofluorescence, Serum (Non-Orderable)


Specimen Required


Only orderable as part of a profile. For more information see:

-DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

-ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

-EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum


Useful For

Only orderable as part of a profile. For more information see:

DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

 

Evaluation of patients suspected to have autoimmune encephalitis using serum specimens

 

Reporting adenylate kinase 5 tissue immunofluorescence results as part of a profile

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
AK5CS AK5 Ab CBA, S No No
AK5TS AK5 Ab IFA Titer, S No No

Method Name

Only orderable as part of a profile. For more information see:

-DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

-ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

-EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

 

Indirect Immunofluorescence Assay (IFA)

Reporting Name

AK5 Ab IFA, S

Specimen Type

Serum

Specimen Minimum Volume

Serum: 1 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Clinical Information

Adenylate kinase 5 IgG (AK5-IgG) is a marker intended for evaluating patients with autoimmune encephalitis, most often presenting as a non-paraneoplastic limbic encephalitis. Poor response to immunotherapy has been reported while there is no clear cancer association (non-paraneoplastic). AK5-IgG positive patients present with predominant severe amnestic syndrome, associated depression, and anxiety. Epilepsy is often absent at disease onset, however seizures may develop later.

Reference Values

Only orderable as part of a profile. For more information see:

-DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum

-ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum

-EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum

 

Negative

Day(s) Performed

Varies

Report Available

5 to 10 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86255